CN Patent

CN119053595A — 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰氨基衍生物

Assigned to Nican Therapy · Expires 2024-11-29 · 1y expired

What this patent protects

本披露提供了某些磺酰氨基衍生物，其是具有式(I)的细胞周期蛋白依赖性激酶2(CDK2)抑制剂，其用于治疗可通过抑制CDK2治疗的疾病。还提供了含有此类化合物的药物组合物以及用于制备此类化合物的方法。

USPTO Abstract

本披露提供了某些磺酰氨基衍生物，其是具有式(I)的细胞周期蛋白依赖性激酶2(CDK2)抑制剂，其用于治疗可通过抑制CDK2治疗的疾病。还提供了含有此类化合物的药物组合物以及用于制备此类化合物的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN119053595A
Jurisdiction
CN
Classification
—
Expires
2024-11-29
Drug substance claim
No
Drug product claim
No
Assignee
Nican Therapy
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.